SCHEMBL7526537

SCHEMBL7526537

Cc1c(C(=O)NN=Cc2ccc(C#N)cc2)[nH]c2cc(Cl)ccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
LMNA P02545 2/20 0.69
THRB P10828 2/20 0.69
TUBB4A P04350 2/20 0.65
TUBB P07437 2/20 0.65
TUBA3C P0DPH7 2/20 0.65
TUBA1B P68363 2/20 0.65
TUBA4A P68366 2/20 0.65
TUBB4B P68371 2/20 0.65
TUBB3 Q13509 2/20 0.65
TUBB2A Q13885 2/20 0.65
TUBB8 Q3ZCM7 2/20 0.65
TUBA3E Q6PEY2 2/20 0.65
TUBA1A Q71U36 2/20 0.65
TUBA1C Q9BQE3 2/20 0.65
TUBB6 Q9BUF5 2/20 0.65
TUBB2B Q9BVA1 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7678818 1.00 MAPT (0.69) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7566603 0.90 MAPT (0.83) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7532157 0.90 MAPT (0.83) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7565788 0.85 TUBB4A (0.61) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7565779 0.85 TUBB4A (0.61) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7671691 0.85 TUBB4A (0.61) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7533253 0.85 TUBB4A (0.61) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7673063 0.84 MAPT (0.70) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7527624 0.84 MAPT (0.70) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL7679523 0.80 MAPT (0.70) MAPTMEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885MEN1 3165/4885KMT2A 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.